Loading…
Jiangxi-based pharmaceutical manufacturer selling generic drugs in China.
Jiangxi-based pharmaceutical manufacturer selling generic drugs in China.
Moat: none
Headquarters: Jiangxi, China · Employees: 1,663
Size Jiangxi Fushine Pharmaceutical (300497.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.10B, the 2130th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥13.73 on 6 Nov 2026.
Performance Over six months the shares fell 28.9%, against -16.5% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 102.6% over the last twelve months (peer median +8.3%); the operating margin is 24.0% (peer median 8.8%).
Valuation It trades at 10.6× forward earnings against a peer median of 23.8× (cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.2 points above its cost of capital (8.3% WACC).
Next results Next results expected around 3 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.97B | CN¥1.18B | CN¥1.17B | CN¥1.61B | CN¥1.64B |
| Revenue growth | — | +1% | -27% | -2% | — |
| Gross profit | CN¥905M | CN¥151M | CN¥19.9M | CN¥108M | CN¥244M |
| EBITDA | n/a | CN¥146M | -CN¥22.0M | -CN¥16.3M | CN¥60.0M |
| Net income | CN¥411M | -CN¥55.0M | -CN¥272M | -CN¥201M | -CN¥141M |
| Free cash flow | CN¥60.0M | -CN¥161M | CN¥46.9M | -CN¥306M | -CN¥579M |
| Capital expenditure | CN¥142M | CN¥225M | CN¥142M | CN¥242M | CN¥459M |
| Total debt | CN¥1.63B | CN¥1.75B | CN¥1.95B | CN¥1.98B | CN¥1.79B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300497.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.7% | -5.5% | 3rd lowest of 21 |
| 6-month return | -28.9% | -16.5% | 8th lowest of 21 |
| Distance from 52-week high | -43.2% | -38.0% | 10th lowest of 21 |
| Revenue growth (TTM) | +102.6% | +8.3% | 2nd highest of 20 |
| Operating margin | 24.0% | 8.8% | 3rd highest of 20 |
| Forward P/E | 10.6× | 23.8× | cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 8.6% | 4.2% | 5th most demanding of 13 |
| Growth delivered (Del g) | -4.5% | +7.1% | 3rd lowest of 13 |
| Hurdle (Req g minus delivered) | +13.0 pp | -0.3 pp | 4th most demanding of 13 |
| ROIC minus cost of capital | +4.2 pp | +0.4 pp | 6th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 10.6× | 8.6% | -4.5% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 49.2× | 13.9% | +4.9% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 26.5× | n/a | n/a |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 26.5× | 5.5% | +7.7% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 27.9× | n/a | n/a |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% | +3.5% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | n/a | 34.1% | -6.0% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 30.3× | 38.6% | +20.4% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% | +12.7% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | n/a | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 12.8× | 1.1% | +22.8% |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 23.8× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 17.7× | -9.4% | -7.0% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 21.0× | 3.4% | +1.8% |